"Autoimmunity"

Autoimmune hepatitis

Is there an impact of sex (biologically male/female) differences between donors and recipients on safety and efficacy of cell therapies for immune system and autoimmune conditions? Skip to main contentSkip to "About this site"Switch to basic HTML versionSearch and menusSearch and menusCanadian Institutesof Health ResearchYou are here:Home Initiatives Drug Safety and Effectiveness NetworkDSEN AbstractIs there an impact of sex (biologically male/female) differences between donors and recipients on safety and efficacy of cell therapies for immune system and autoimmune conditions?Other formatPDF version(192 KB)What is the current situation?Allogeneic and autologous hematopoietic stem cell transplantation (HSCT) has been increasingly used as a potentially life-saving treatment for severe autoimmune

COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders | Guidance | NICE 1. Home 2. NICE Guidance 3. Conditions and diseases 4. Infections 5. COVID-19 COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders NICE

Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) Health Evidence Review Commission (HERC) Coverage Guidance: Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) Approved 5/19/2022 HERC Coverage Guidance Tonsillectomy, adenoidectomy, adenotonsillectomy, plasma exchange, and prophylactic antibiotic therapy are not recommended for coverage to treat pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS) (weak recommendation). Up to 3 monthly immunomodulatory courses of intravenous

ASCIA Position Paper - Laboratory Tests for Autoimmune Diseases Home Health Professionals Laboratory Tests for Autoimmune DiseasesLaboratory Tests for Autoimmune Diseases Position PaperThis document has been developed by ASCIA, the peak professional body of clinical immunology/allergy specialists in Australia and New Zealand. ASCIA information is based on published literature and expert review , is not influenced by commercial organisations and is not intended to replace medical advice. Patient and carer support organisations are listed at www.allergy.org.au/patients/patient-support-organisations.ASCIA HP Autoimmune Diseases Laboratory Testing 2023181.80 KBOverview of tests for autoimmune diseasesA diagnosis of autoimmune diseases is obtained by using a combination of:Detailed clinical history,Physical

Alternative Therapies to Immunoglobulin for Autoimmune Blistering Diseases Return to Article DetailsAlternative Therapies to Immunoglobulin for Autoimmune Blistering Diseases

2023 American College of Rheumatology (ACR) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Disease: Guideline Summary 1 2023 American College of Rheumatology (ACR) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Disease Guideline Summary This guideline provides evidence-based recommendations for the treatment of Interstitial Lung Disease (ILD) in adults with Systemic Autoimmune Rheumatic Diseases (SARDs) at greatest risk of ILD, including systemic sclerosis (SSc), rheumatoid arthritis (RA), idiopathic inflammatory myopathies (IIM including polymyositis, dermatomyositis, antisynthetase syndrome, immune-mediated necrotizing myopathy), mixed connective tissue disease (MCTD

2023 American College of Rheumatology (ACR) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Disease: Guideline Summary 1 2023 American College of Rheumatology (ACR) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Disease Guideline Summary This guideline was developed to provide recommendations for the screening of Interstitial Lung Disease (ILD) in people with Systemic Autoimmune Rheumatic Diseases (SARDs) [Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Idiopathic Inflammatory Myositis (IIM including polymyositis, dermatomyositis, antisynthetase syndrome, immune-mediated necrotizing myopathy), Mixed Connective Tissue Disease (MCTD), and Sjögren's

Alternative Therapies to Immunoglobulin for Autoimmune Blistering Diseases Skip to main contentToggle SearchToggle MenuAlternative Therapies to Immunoglobulin for Autoimmune Blistering DiseasesHome Alternative Therapies to Immunoglobulin for Autoimmune Blistering DiseasesDetailsFiles Project Status:CompletedProject Line:Health Technology ReviewProject Sub Line:Summary with Critical AppraisalProject Number:RC1483-000QuestionWhat is the clinical effectiveness of alternative treatments to IVIg compared to IVIg or placebo for autoimmune blistering diseases?What is the safety of alternative treatments to IVIg compared to IVIg or placebo for autoimmune blistering diseases?What are the evidence-based guidelines regarding the use of alternative treatments to IVIg for autoimmune blistering diseases

Evidence for Long-term Impacts of COVID-19 on Immune Cells and Autoimmune Conditions in Adults ' What We Know So Far Evidence for Long-term Impacts of COVID-19 on Immune Cells and Autoimmune Conditions in Adults – What We Know So Far 1 SYNTHESIS Evidence for Long-term Impacts of COVID-19 on Immune Cells and Autoimmune Conditions in Adults – What We Know So Far Published: August 2023 coronavirus 2 (SARS-CoV-2) infection on immune cells and autoimmune conditions. Key Findings  Patients with post-acute COVID-19 syndrome (PASC) or patients in the post-acute stage of disease (≥3 months post-symptom onset) have elevated cluster of differentiation 8 (CD8+) T-cell levels, compared to patients with non-PASC, healthy controls and those with acute disease. Elevated expression of CD8+ T-cell pro

Amendment of the Japanese consensus guidelines for autoimmune pancreatitis, 2020 PROSPEROInternational prospective register of systematic reviews Print | PDFDoes preexisting moderate and severe mitral regurgitation require simultaneous repair in patients receiving left ventricular assist device implantation? an updated systematic review and meta-analysisWang Zhihua, Zhao ZeyuanTo enable

EULAR/PRES recommendations for vaccination of paediatric patients with autoimmune inflammatory rheumatic diseases Skip to main contentSubscribe Log In Basket Search Latest content Current issue Archive Authors Podcasts AboutYou are hereHome Archive Volume 82, Issue 1Email alertsArticleTextArticleinfoCitationToolsShareRapid ResponsesArticlemetricsAlertsPDFRecommendationEULAR/PRES recommendations for vaccination of paediatric patients with autoimmune inflammatory rheumatic diseases: update 2021 FREEhttp://orcid.org/0000-0001-6969-8759Marc H A Jansen1,2, Christien Rondaan3, Geertje E Legger2,4, Kirsten Minden5,6, http://orcid.org/0000-0003-4655-1652Yosef Uziel7, Natasa Toplak2,8, Despoina Maritsi9, Lotte van den Berg10, Guy A M Berbers11, Patricia Bruijning12, Yona Egert13, Christophe Normand14, Marc

Trio-based exome sequencing and high-resolution HLA typing in families of patients with autoimmune adrenal insufficiency and autoimmune polyglandular syndrome. Autoimmune adrenal insufficiency (AAI) is a rare disease. This research evaluates three patients with AAI, including autoimmune polyglandular syndrome (APS) type 2. Two patients had APS or AAI during childhood, and one had a history of endocrine autoimmune disease, indicating a possible hereditary basis of the condition. Trio-based exome sequencing and high-resolution HLA typing were employed to analyze patients and their parents. Benign or likely benign variants of the AIRE gene were identified in all participants of the study. These variants, coupled with clinical data and the results of antibody studies to type I interferons, helped

CRA Recommendation on COVID-19 Vaccination in Persons with Autoimmune Rheumatic Disease 1 CRA Recommendation on Covid-19 Vaccination in Persons with Autoimmune Rheumatic Disease Version 2.0 May 20, 2021 Highlights of Changes: • Updated to include ChAdOx1 (AstraZeneca Oxford; Serum Institute of India) and Ad26.COV2.S (Johnson & Johnson) vaccines, in addition to BNT 162b2 (Pfizer-BioNTech ) and mRNA-1273 (Moderna). The Canadian Rheumatology Association guideline panel suggests using COVID-19 vaccination in persons with autoimmune rheumatic disease. (Conditional recommendation, low certainty of the evidence about effects for BNT 162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna) and Ad26.COV2.S (Johnson & Johnson); very low certainty for ChAdOx1 (AstraZeneca)) Remarks: This recommendation

Rituximab therapy for the treatment of nodal/paranodal antibody positive inflammatory/autoimmune neuropathy in adults and postpubescent children NHS England » Rituximab therapy for the treatment of nodal/paranodal antibody positive inflammatory/autoimmune neuropathy in adults and postpubescent children Skip to main content Cookies on the NHS England websiteWe’ve put some small files called website.Rituximab therapy for the treatment of nodal/paranodal antibody positive inflammatory/autoimmune neuropathy in adults and postpubescent childrenDocument first published: 1 October 2021 Page updated: 15 October 2021 Topic: Specialised commissioning Publication type: Policy or strategy Rituximab is recommended to be available as a treatment option through routine commissioning for nodal/paranodal antibody

Allergy, Immunodeficiency, Autoimmunity and COVID-19 Vaccination - Position Statement for health professionals ASCIA HP Position Statement COVID-19 Vaccination - Australasian Society of Clinical Immunology and Allergy (ASCIA) * Home * About Us * About ASCIA * About Clinical Immunology and Allergy * About ASCIA e-training * AIFA * ASCIA Collaborations * ASCIA Education Diseases Register * Position Papers/Guidelines * ASCIA HP Position Statement COVID-19 Vaccination * Guide: COVID-19 Vaccination for Clinical Immunology/Allergy Specialists * Guide: Allergy and COVID-19 Vaccination * Guide: Immunodeficiency, Autoimmunity and COVID-19 Vaccination * ASCIA Clinical Update Allergic Rhinitis * ASCIA

Immunodeficiency, Autoimmunity and COVID-19 Vaccination - Guide for health professionals Guide: Immunodeficiency, Autoimmunity and COVID-19 Vaccination - Australasian Society of Clinical Immunology and Allergy (ASCIA) * Home * About Us * About ASCIA * About Clinical Immunology and Allergy * About ASCIA e-training * AIFA * ASCIA Collaborations * ASCIA Education Projects * Position Papers/Guidelines * ASCIA HP Position Statement COVID-19 Vaccination * Guide: COVID-19 Vaccination for Clinical Immunology/Allergy Specialists * Guide: Allergy and COVID-19 Vaccination * Guide: Immunodeficiency, Autoimmunity and COVID-19 Vaccination * ASCIA Clinical Update Allergic Rhinitis * ASCIA References Allergic Rhinitis * ASCIA Position Paper

CRA Recommendation on COVID-19 Vaccination in Persons with Autoimmune Rheumatic Disease 1 280-13300 Tecumseh Rd E., Suite 386, Tecumseh, ON N8N 4R8 T: (905) 952-0698 | E: info@rheum.ca RHEUM.CA CRA Recommendation on COVID-19 Vaccination in Persons with Autoimmune Rheumatic Disease Version 3.0 November 23, 2021 Highlights of changes: • Extended the recommendation to include the use of mRNA with autoimmune rheumatic disease. (Conditional recommendation, low certainty of the evidence about effects for age >=18 BNT 162b2 (Pfizer-BioNTech), age >=18 mRNA-1273 (Moderna) and age >=18 Ad26.COV2.5 (Johnson & Johnson); very low certainty for age >=18 ChAdOx1 (AstraZeneca), age 12-17 BNT 162b2 (Pfizer-BioNTech)) Remarks: • This recommendation is based on evidence for currently approved COVID-19 vaccines

Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee www.thelancet.comVerifying you are human. This may take a few seconds.www.thelancet.com needs to review the security of your connection before proceeding.Ray ID: 8642d92cadda88a4Performance & security

Differential diagnosis and comparison of diagnostic algorithms in children and adolescents with autoimmune encephalitis in Spain: a prospective cohort study and retrospective analysis The usefulness of current diagnostic approaches in children with suspected autoimmune encephalitis is unknown. We aimed to assess the diagnosis of autoimmune encephalitis in clinical practice and to compare the performance of two international diagnostic algorithms (one intended for patients of any age [general], the other intended for paediatric patients), with particular emphasis on the evaluation of patients with probable antibody-negative autoimmune encephalitis because this diagnosis suggests that immunotherapy should be continued or escalated but is difficult to establish. We did a prospective cohort study